Suppressive effects of S-methyl methanethiosulfonate on promotion stage of diethylnitrosamine-initiated and phenobarbital-promoted hepatocarcinogenesis model.
Modifying effects of S-methyl methanethiosulfonate (MMTS) on diethylnitrosamine (DEN)-initiated and phenobarbital (PB)-promoted hepatocarcinogenesis were examined in rats. Five-week-old male F344 rats were divided into 8 groups. After a week, groups 1-5 were given DEN (100 mg/kg body weight, i.p.) once a week for 3 weeks, whereas groups 6-8 received vehicle treatment. Group 2 was given 100 ppm MMTS containing diet in the initiation phase. From 4 weeks after the start of experiment, groups 3 and 5 were fed MMTS, and groups 1-3 and 7 received drinking water containing 500 ppm PB. Group 6 was given MMTS diet alone throughout the experiment (24 weeks). The incidences of hepatocellular adenoma and total liver tumors were significantly smaller in group 3 than those of group 1. The average numbers of hepatocellular adenoma, carcinoma and total tumors in group 3 were significantly smaller than in group 1. Glutathione S-transferase placental form-positive foci were also significantly decreased by MMTS treatment in the promotion phase. MMTS treatment in the initiation or promotion phase reduced ornithine decarboxylase activity in the liver of rats given DEN. The antioxidant activity against lipid peroxidation of MMTS was confirmed in tests with rabbit erythrocyte membrane ghosts or rat hepatocytes. These results suggest that MMTS is a promising chemopreventive agent for liver neoplasia when concurrently administered with PB.
Sugie
S
S
Department of Pathology, Institute of Laboratory Animals, Gifu University School of Medicine, Tsukasa-machi.
Okamoto
K
K
Ohnishi
M
M
Makita
H
H
Kawamori
T
T
Watanabe
T
T
Tanaka
T
T
Nakamura
Y K
YK
Nakamura
Y
Y
Tomita
I
I
Mori
H
H
D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D004052:Diethylnitrosamine / Q000633:toxicity; D015227:Lipid Peroxidation / Q000187:drug effects; D008114:Liver Neoplasms, Experimental / Q000517:prevention & control*; D008297:Male; D008741:Methyl Methanesulfonate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009955:Ornithine Decarboxylase / Q000378:metabolism; D010634:Phenobarbital / Q000633:toxicity; D011817:Rabbits; D051381:Rats; D011916:Rats, Inbred F344
D016588:Anticarcinogenic Agents; C014674:methyl methanethiosulfonate; D004052:Diethylnitrosamine; D008741:Methyl Methanesulfonate; D009955:Ornithine Decarboxylase; D010634:Phenobarbital